DoD Melanoma, Translational Research Award

archived

The FY19 MRP Translational Research Award supports hypothesis-driven, translational, high-impact research. The Translational Research Award mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical melanoma issues, which, if successfully addressed, have the potential to make a major impact. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples from clinical trials and/or biorepositories. The Translational Research Award supports identifying scientific outcomes, through rigorous, robust research, that are translatable toward treatment and/or preventive strategies. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact. Proposed studies should focus on the commonalities in melanoma research to advance the understanding of the field The Translational Research Award is not intended to study research into established late-stage disease models, clinical utility of PD-1 in combination with other therapeutics, or established cell lines. The MRP is not requesting research into established macrometastatic disease, models of metastatic disease using established cell lines, or treatment of macrometastatic disease. Studies involving non-melanoma skin cancers are not allowed under the FY19 MRP.

High